Daxor Corporation Announces Replay of Nasdaq Closing Bell Ceremony Now Available
Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, has made available the replay of its Nasdaq Closing Bell Ceremony from August 8, 2025. The ceremony celebrated a significant milestone: the FDA 510(k) clearance for the company's new Daxor BVA™ (Blood Volume Analyzer).
The next-generation device is characterized as a patent-pending, rapid, compact, and hand-held blood volume measurement system designed for lab-based use.
Daxor Corporation (NASDAQ: DXR) ha reso disponibile la registrazione della cerimonia di chiusura del Nasdaq dell'8 agosto 2025. La cerimonia ha celebrato un traguardo importante: l'autorizzazione 510(k) della FDA per il nuovo Daxor BVA™ (Analizzatore del Volume Sanguigno) dell'azienda.
Il dispositivo di nuova generazione è un sistema di misurazione del volume sanguigno con domanda di brevetto in corso, rapido, compatto e portatile, progettato per l'uso in laboratorio.
Daxor Corporation (NASDAQ: DXR) ha puesto a disposición la grabación de su ceremonia de toque de campana de cierre en Nasdaq del 8 de agosto de 2025. La ceremonia celebró un hito importante: la autorización 510(k) de la FDA para el nuevo Daxor BVA™ (Analizador de Volumen Sanguíneo) de la compañía.
El dispositivo de nueva generación es un sistema de medición del volumen sanguíneo pendiente de patente, rápido, compacto y de mano, diseñado para su uso en laboratorio.
Daxor Corporation (NASDAQ: DXR)는 2025년 8월 8일 열린 나스닥 폐장 종소리 행사 녹화 영상을 공개했습니다. 이 행사는 회사의 신제품 Daxor BVA™ (혈액량 분석기)에 대한 중요한 이정표인 FDA 510(k) 허가를 기념했습니다.
이 차세대 기기는 연구실용으로 설계된 혈액량 측정 시스템으로, 특허 출원 중이며 빠르고 소형에 휴대 가능한 특징을 갖추고 있습니다.
Daxor Corporation (NASDAQ: DXR) a rendu disponible la rediffusion de sa cérémonie de clôture du Nasdaq du 8 août 2025. La cérémonie a célébré une étape importante : l'autorisation 510(k) de la FDA pour le nouveau Daxor BVA™ (Analyseur de volume sanguin) de l'entreprise.
Ce dispositif de nouvelle génération est un système de mesure du volume sanguin en instance de brevet, rapide, compact et portable, conçu pour une utilisation en laboratoire.
Daxor Corporation (NASDAQ: DXR) hat die Aufzeichnung seiner Nasdaq-Schlussglocken-Zeremonie vom 8. August 2025 veröffentlicht. Die Zeremonie würdigte einen bedeutenden Meilenstein: die FDA-510(k)-Zulassung für das neue Daxor BVA™ (Blutvolumen-Analysator) des Unternehmens.
Das Gerät der nächsten Generation ist ein System zur Messung des Blutvolumens, mit anhängiger Patentanmeldung, schnell, kompakt und handlich, das für den Laboreinsatz konzipiert wurde.
- Received FDA 510(k) clearance for next-generation Daxor BVA™
- Successfully developed a compact, hand-held version of their blood volume measurement technology
- None.
The celebration marks a major milestone for the patent-pending, next-generation, rapid, compact, and hand-held Daxor BVA™.
Oak Ridge, TN, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces that the official replay of its Nasdaq Closing Bell Ceremony is now available. The ceremony, which took place on August 8, 2025, commemorated the FDA 510(k) clearance for its patent-pending, next-generation, rapid, compact, hand-held, lab-based new Daxor BVA™ (Blood Volume Analyzer).
You can watch the full replay of the event here: Closing Ceremony.
For more information, visit daxor.com.
Sign up to receive news on Daxor’s innovative technology HERE.
About Daxor Corporation
Daxor Corporation (NASDAQ: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor's patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Investor Relations Contact:
Bret Shapiro
COO – Head of Capital Markets
COREIR
(561)-479-8566-Cell
brets@coreir.com|www.coreir.com
FAQ
What milestone did Daxor (NASDAQ: DXR) celebrate at the Nasdaq Closing Bell Ceremony?
When did Daxor (DXR) ring the Nasdaq Closing Bell?
What are the key features of Daxor's new Blood Volume Analyzer?
Where can investors watch Daxor's Nasdaq Closing Bell Ceremony?
